Abstract
Accelerated and blast phase myeloproliferative neoplasms are advanced stages of the disease with historically a poor prognosis and little improvement in outcomes thus far. The lack of responses to standard treatments likely results from the more aggressive biology reflected by the higher incidence of complex karyotype and high-risk somatic mutations, which are enriched at the time of transformation. Treatment options include induction chemotherapy (7 + 3) as that used on de novo acute myeloid leukemia or hypomethylating agent–based therapy, which has shown similar outcomes. Allogeneic stem cell transplantation remains the only potential for cure.
Original language | English (US) |
---|---|
Pages (from-to) | 325-335 |
Number of pages | 11 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 35 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2021 |
Keywords
- Accelerated phase
- Acute myeloid leukemia
- Blast phase
- Myeloproliferative neoplasm
ASJC Scopus subject areas
- Hematology
- Oncology